An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
This is a Phase 3 trial comparing the safety and anti-tumor activity of PF-02341066 versus pemetrexed or docetaxel in patients with advanced non-small cell lung cancer with specific gene profile involving the ALK gene after failure of one previous chemotherapy regimen that included one platinum drug.
Checked against the public recordLast updated Jan 2, 2017 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 3
- Sponsor
- Pfizer
- Interventions being studied
- Drug: PF-02341066; Drug: Pemetrexed; Drug: Docetaxel
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * histologically or cytologically proven diagnosis of non-small cell lung cancer * positive for the ALK fusion gene (test provided by a central laboratory) * must have had disease progression after only one prior chemotherapy and that regimen but must have included one platinum drug * tumors must be measurable Exclusion Criteria: * prior treatment with PF-02341066 * current treatment in another clinical trial
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of Arkansas for Medical Research, Winthrop Rockefeller Cancer InstituteLittle Rock, Arkansas
- Comprehensive Blood and Cancer CenterBakersfield, California
- Tower Cancer Research FoundationBeverly Hills, California
- Tower Hematology Oncology Medical GroupBeverly Hills, California
- UCSD Medical Center -La JollaLa Jolla, California
- Moores UC San Diego Cancer CenterLa Jolla, California
- Drug Shipping Address: [IRB# 10-001530] Ronald Reagan UCLALos Angeles, California
- Ronald Reagan UCLA Medical CenterLos Angeles, California
- UCLA Hematology OncologyLos Angeles, California
- UCLA Ophthalmic Oncology CenterLos Angeles, California
- University of California-Los AngelesLos Angeles, California
- Ship Drug To : Kevin Kong- University of California, Irvine-PharmacyOrange, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 2, 2017. Always confirm current availability with the study team.